TECHNOLOGY LICENSING OPPORTUNITY: PlagueGuard Antibodies

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

S-133813

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
Documents2
Los Alamos National Laboratory (LANL), operating under the TRIAD - DOE CONTRACTOR, has issued a special notice regarding a technology licensing opportunity for "PlagueGuard Antibodies." This initiative is not a solicitation for external development services, but rather an invitation for companies to license a patented innovation developed by LANL scientists. The technology centers on high-affinity human antibodies designed to rapidly detect and potentially treat infections caused by Yersinia pestis, the bacterium responsible for plague. This advancement addresses critical challenges in both public health and biodefense, particularly the growing threat of antibiotic-resistant strains and the need for reliable, field-deployable diagnostics. Purpose and Scope: The primary objective of this licensing opportunity is to facilitate the commercial application of LANL’s proprietary antibodies, which exhibit exceptional sensitivity and specificity for the F1 antigen—a key marker of virulent Y. pestis strains. These antibodies are engineered to recognize two distinct epitopes on the antigen, significantly reducing the risk of false positives and enhancing diagnostic accuracy. Their robust design allows for chemical modification, enabling use in both rapid diagnostic platforms (such as lateral flow assays) and therapeutic modalities, including radioimmunotherapy. The technology is positioned at Technology Readiness Level (TRL) 5, indicating successful validation in relevant environments. Key Requirements and Deliverables: Interested parties are expected to engage in licensing discussions for the patented technology (US Patent No. 11,702,465, reference LA-UR-25-28651). LANL offers both exclusive and non-exclusive licensing agreements, suitable for established firms and startups alike. The deliverables for licensees include access to the antibody technology and associated intellectual property, with the expectation that licensees will further develop, manufacture, and commercialize products for diagnostic, therapeutic, or biosafety applications. The antibodies’ dual utility—diagnostic and therapeutic—opens opportunities in public health, pharmaceutical development, biodefense, radiopharmaceuticals, and veterinary/agricultural biosafety. Contracting Entity and Location: The contracting entity is TRIAD - DOE CONTRACTOR, a federal office based at Los Alamos National Laboratory in Los Alamos, New Mexico (NAICS Code: 325414, Biological Product (except Diagnostic) Manufacturing; Product Service Code: 6505). The place of performance is Los Alamos, NM, United States. Procurement Type and Special Considerations: This is a technology licensing opportunity, not a procurement for goods or services. There are no set-aside requirements, and the notice is open to all qualified entities interested in commercializing the technology. LANL’s licensing program is designed to transition laboratory inventions into market-ready innovations, supporting both exclusive and non-exclusive arrangements. Companies are encouraged to leverage LANL’s broader portfolio of technologies and capabilities to enhance their competitive position. Contact Information: For further information or to initiate licensing discussions, interested parties should contact Mike Erickson or Lindsay Augustyn at [email protected]. Additional details about LANL’s technology transfer and partnership programs can be found at the following URLs: - https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology - https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search Timeline and Status: The notice was posted on May 12, 2025, and responses are due by October 10, 2025. The opportunity is currently active and listed on SAM.gov (Opportunity ID: f98c4e71a90543cf9b114d8a8298af5d). Summary: This licensing opportunity represents a significant advancement in the detection and treatment of plague, with broad applications across public health, biodefense, and pharmaceutical sectors. The technology’s resilience against antibiotic resistance and its adaptability for both diagnostic and therapeutic uses make it a compelling option for companies seeking to expand their portfolio in infectious disease management and biosafety. Interested parties should review the patent details and contact LANL’s licensing office to explore partnership possibilities.